MDMB-BINACA
From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C19H27N3O3 |
| Molar mass | 345.443 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MDMB-BINACA (MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Sweden in May 2023. It has a similar chemical structure to potent cannabinoid agonists previously reported such as ADB-BUTINACA and MDMB-5'Br-BUTINACA, and is believed to have similar effects.[1]
See also
[edit ]References
[edit ]- ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.
| Receptor (ligands) |
| ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (modulators) |
| ||||||||||||||||||||||||||||||
| Enzyme (modulators) |
| ||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
Stub icon
This cannabinoid related article is a stub. You can help Wikipedia by expanding it.
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Short description is different from Wikidata
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All stub articles